Skip to main content
. Author manuscript; available in PMC: 2016 Nov 21.
Published in final edited form as: ChemMedChem. 2016 Sep 14;11(19):2188–2193. doi: 10.1002/cmdc.201600072

Figure 3.

Figure 3

Effect of N-NE3TA-based anti-tumor agents and clinically available drug DFO on viability of HeLa, HT29, and PC3 cancer cells. Cell viability data (mean ± SD%) was measured in triplicate. The cell viability data of the known chelators DFO and N-NE3TA in HeLa and HT29 were cited for comparison.10